Cargando…

Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale

Introduction: To ensure the quality of clinical trial safety data, universal data standards are required. In 2019 the International Neonatal Consortium (INC) published a neonatal adverse event severity scale (NAESS) to standardize the reporting of adverse event (AE) severity. In this study the relia...

Descripción completa

Detalles Bibliográficos
Autores principales: Salaets, Thomas, Lacaze-Masmonteil, Thierry, Hokuto, Isamu, Gauldin, Cheri, Taha, Amjad, Smits, Anne, Thewissen, Liesbeth, Van Horebeek, Ilse, Shoraisham, Armuchou, Mohammad, Khorshid, Suzuki, Manami, Komachi, Shiori, Michels, Kurt, Turner, Mark A., Allegaert, Karel, Lewis, Tamorah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512550/
https://www.ncbi.nlm.nih.gov/pubmed/37745081
http://dx.doi.org/10.3389/fphar.2023.1237982
_version_ 1785108385092337664
author Salaets, Thomas
Lacaze-Masmonteil, Thierry
Hokuto, Isamu
Gauldin, Cheri
Taha, Amjad
Smits, Anne
Thewissen, Liesbeth
Van Horebeek, Ilse
Shoraisham, Armuchou
Mohammad, Khorshid
Suzuki, Manami
Komachi, Shiori
Michels, Kurt
Turner, Mark A.
Allegaert, Karel
Lewis, Tamorah
author_facet Salaets, Thomas
Lacaze-Masmonteil, Thierry
Hokuto, Isamu
Gauldin, Cheri
Taha, Amjad
Smits, Anne
Thewissen, Liesbeth
Van Horebeek, Ilse
Shoraisham, Armuchou
Mohammad, Khorshid
Suzuki, Manami
Komachi, Shiori
Michels, Kurt
Turner, Mark A.
Allegaert, Karel
Lewis, Tamorah
author_sort Salaets, Thomas
collection PubMed
description Introduction: To ensure the quality of clinical trial safety data, universal data standards are required. In 2019 the International Neonatal Consortium (INC) published a neonatal adverse event severity scale (NAESS) to standardize the reporting of adverse event (AE) severity. In this study the reliability of AE severity grading with INC NAESS was prospectively assessed in a real-world setting. Methods: Severity of AEs was assessed by two independent observers at each of four centers across the world. In each center two series of 30 neonatal adverse events were assessed by both observers: in a first phase with a generic (Common Terminology Criteria for Adverse Events, CTCAE) severity scale not specific to neonates, and in a second phase with INC NAESS (after a structured training). Intraclass correlation coefficients (ICC) were calculated to express inter-rater agreement in both phases, and bootstrap sampling was used to compare them. Results: 120 AEs were included in each of both phases. The ICC with the use of INC NAESS in phase 2 was 0.69. This represents a significant but modest improvement in comparison to the initial ICC of 0.66 in phase 1 (confidence interval of ratio of ICC in phase 2 to phase 1 = 1.005–1.146; excludes 1). The ICC was higher for those AEs for which a diagnosis specific AE severity table was available in INC NAESS (ICC 0.80). Discussion: Good inter-rater reliability of the INC NAESS was demonstrated in four neonatal intensive care units (NICUs) across the globe. The ICC is comparable to what is reported for scales with similar purposes in different populations. There is a modest, but significant, improvement in inter-rater agreement in comparison to the naïve phase without INC NAESS. The better performance when reviewers use AE-specific NAESS tables highlights the need to expand the number of AEs that are covered by specific criteria in the current version of INC NAESS.
format Online
Article
Text
id pubmed-10512550
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105125502023-09-22 Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale Salaets, Thomas Lacaze-Masmonteil, Thierry Hokuto, Isamu Gauldin, Cheri Taha, Amjad Smits, Anne Thewissen, Liesbeth Van Horebeek, Ilse Shoraisham, Armuchou Mohammad, Khorshid Suzuki, Manami Komachi, Shiori Michels, Kurt Turner, Mark A. Allegaert, Karel Lewis, Tamorah Front Pharmacol Pharmacology Introduction: To ensure the quality of clinical trial safety data, universal data standards are required. In 2019 the International Neonatal Consortium (INC) published a neonatal adverse event severity scale (NAESS) to standardize the reporting of adverse event (AE) severity. In this study the reliability of AE severity grading with INC NAESS was prospectively assessed in a real-world setting. Methods: Severity of AEs was assessed by two independent observers at each of four centers across the world. In each center two series of 30 neonatal adverse events were assessed by both observers: in a first phase with a generic (Common Terminology Criteria for Adverse Events, CTCAE) severity scale not specific to neonates, and in a second phase with INC NAESS (after a structured training). Intraclass correlation coefficients (ICC) were calculated to express inter-rater agreement in both phases, and bootstrap sampling was used to compare them. Results: 120 AEs were included in each of both phases. The ICC with the use of INC NAESS in phase 2 was 0.69. This represents a significant but modest improvement in comparison to the initial ICC of 0.66 in phase 1 (confidence interval of ratio of ICC in phase 2 to phase 1 = 1.005–1.146; excludes 1). The ICC was higher for those AEs for which a diagnosis specific AE severity table was available in INC NAESS (ICC 0.80). Discussion: Good inter-rater reliability of the INC NAESS was demonstrated in four neonatal intensive care units (NICUs) across the globe. The ICC is comparable to what is reported for scales with similar purposes in different populations. There is a modest, but significant, improvement in inter-rater agreement in comparison to the naïve phase without INC NAESS. The better performance when reviewers use AE-specific NAESS tables highlights the need to expand the number of AEs that are covered by specific criteria in the current version of INC NAESS. Frontiers Media S.A. 2023-09-07 /pmc/articles/PMC10512550/ /pubmed/37745081 http://dx.doi.org/10.3389/fphar.2023.1237982 Text en Copyright © 2023 Salaets, Lacaze-Masmonteil, Hokuto, Gauldin, Taha, Smits, Thewissen, Van Horebeek, Shoraisham, Mohammad, Suzuki, Komachi, Michels, Turner, Allegaert and Lewis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Salaets, Thomas
Lacaze-Masmonteil, Thierry
Hokuto, Isamu
Gauldin, Cheri
Taha, Amjad
Smits, Anne
Thewissen, Liesbeth
Van Horebeek, Ilse
Shoraisham, Armuchou
Mohammad, Khorshid
Suzuki, Manami
Komachi, Shiori
Michels, Kurt
Turner, Mark A.
Allegaert, Karel
Lewis, Tamorah
Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
title Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
title_full Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
title_fullStr Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
title_full_unstemmed Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
title_short Prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
title_sort prospective assessment of inter-rater reliability of a neonatal adverse event severity scale
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512550/
https://www.ncbi.nlm.nih.gov/pubmed/37745081
http://dx.doi.org/10.3389/fphar.2023.1237982
work_keys_str_mv AT salaetsthomas prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT lacazemasmonteilthierry prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT hokutoisamu prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT gauldincheri prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT tahaamjad prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT smitsanne prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT thewissenliesbeth prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT vanhorebeekilse prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT shoraishamarmuchou prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT mohammadkhorshid prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT suzukimanami prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT komachishiori prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT michelskurt prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT turnermarka prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT allegaertkarel prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale
AT lewistamorah prospectiveassessmentofinterraterreliabilityofaneonataladverseeventseverityscale